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Serendipity meets precision: the integration of structure-based drug
design and combinatorial chemistry for efficient drug discovery
F Raymond Salemme, John Spurlino and Roger Bone
Structure-based drug design uses three-dimensional
visualization of drug candidates bound to a target receptor
to direct structural modifications that increase potency.
This widely used approach is limited by the difficulty of
accurately predicting drug-binding affinities from three-
dimensional structures. The integration of structure-based
drug design with combinatorial chemistry can overcome
this limitation by providing an empirical understanding of
drug-binding energies. This integration allows compound
synthesis and evaluation in parallel, and also helps assure
that the compounds produced have properties consistent
with good bioavailability and safety. 
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Structure-based drug design uses the three-dimensional
structures of complexes made up of a receptor and a ‘lead’,
or candidate drug, as determined by X-ray crystallography
or NMR methods, to direct the atom-by-atom modi-
fication and improvement of drug leads [1]. Although
structure-based design has become widely used in phar-
maceutical discovery, fundamental technical issues still
limit its efficiency.
Determination of the initial drug-lead structure is just the
first step of the drug-optimization process. Optimization is
rate limited by the requirement for many rounds of syn-
thesis, activity characterization, and structural analysis in
order to map the detailed binding-site energetics for the
interactions between the drug and its target protein. It is
not possible to simply translate a three-dimensional view
of the drug bound to its target protein into new com-
pounds with improved potency, because of the physical
complexity underlying the free-energy change that accom-
panies the binding of a ligand to a macromolecule in water
(Fig. 1) [2–4]. Ligand binding involves a multiplicity of
factors, including changes in intermolecular interactions
between the ligand, the solvent water and the target
protein, as well as changes in ligand or receptor polariza-
tion, conformation or flexibility. The accurate estimation
of how these changes occur and how they affect ligand
binding lies beyond the practical capabilities of present
computational methods. Consequently, investigators typi-
cally carry out iterative synthesis and structural analysis of
an extensive series of compounds in order to define the
important aspects of ligand-binding energetics empiri-
cally, and so to refine the properties of drug candidates.
Furthermore, structure-based design is limited by its focus
on the enhancement of drug potency and specificity: it
provides little direction for ensuring or improving in vivo
properties, such as bioavailability or safety. These latter
properties, which often determine whether a drug can-
didate is ultimately developed, are exceedingly difficult 
to predict quantitatively. Thus far, structure-based drug
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A schematic showing the structural correlates of the components of
free-energy changes associated with the binding of a drug (ligand) to a
macromolecule (receptor) in solvent. Although X-ray crystallography
can visualize these effects, accurate estimates of the energetics
involved present formidable computational challenges. 
designers have mainly used structural information to intro-
duce chemical groups which are known from medicinal
chemistry experience to aid bioavailability or safety in
ways that will not adversely affect binding affinity. 
Combinatorial chemistry approaches are based on the
development of highly reliable reaction protocols that
allow the synthesis of vast numbers of compounds through
the exhaustive combination of all possible reactions at two
or more sites [5,6]. The development of highly reliable
chemical reactions also enables the simultaneous auto-
mated synthesis of up to 103 individual compounds. The
power of combinatorial chemistry to allow the parallel
synthesis of compounds forms an effective complement 
to structure-based design methods. This integration can
be accomplished by placing the process under computer
control [7], which enables the simultaneous refinement 
of multiple drug properties. An overall view of how this
complementarity works can be illustrated by outlining its
application to a long-standing problem in drug discovery,
the development of orally active, small-molecule throm-
bin inhibitors. 
The development of inhibitors of thrombin
Thrombin is a serine protease that plays a central role in
thrombosis: it functions as the key inducer of fibrin-clot
formation, the most potent activator of platelets, and also
amplifies its own production. Despite an extensive knowl-
edge of thrombin structure and function and the avail-
ability of inhibitors that act at picomolar concentrations
[8–11], the development of safe, orally active agents has
proved an elusive objective. Development has been hin-
dered by problems relating to lack of specificity [12] and
poor oral bioavailability. 
Combinatorial libraries targeted to inhibit enzyme or recep-
tor function can be either based on transition-state analog
approaches that exploit the active-site catalytic machin-
ery [13,14], or geometrically directed to make specific
interactions with substrate or cofactor subsites. A general 
drawback of the transition-state analog approach for drug
design is that whatever binding energy is gained through
active-site interactions, it is often accompanied by a com-
mensurate loss in specificity towards other enzymes that
share the same catalytic mechanism. Although approaches
to drug development based on transition-state analogs have
led to potent inhibitors of serine proteases, including
thrombin [8,9,11], lack of specificity [12] and poor bioavail-
ability have thus far prevented the successful development
of these compounds as drugs. However, serine proteases
typically have well defined binding subsites associated
with substrate-recognition specificity, which can potentially
provide the basis for potent and specific inhibitors. 
The development of novel combinatorial chemistry ‘scaf-
folds’ or core structures that can be used to investigate
subsite-binding energetics has similar problems to those
encountered in designing drugs de novo, directly from the
three-dimensional protein structures [1,15]. Although the
ability to produce many compounds through parallel syn-
thesis greatly increases that rate at which individual 
compounds can be synthesized and evaluated [7,16], 
the development of broadly reliable chemistry to allow
320 Structure 1997, Vol 5 No 3
Table 1
Ki values (mM) of thrombin combinatorial library members
based on D-Phe–Pro-test scaffold.
Test group (X)*
Protease 1 2 3 4 5
Thrombin 0.35 2.6 4.1 2.9 15
Plasmin (0)† (0)** (0)¶ 15 (0)††
Urokinase (0)† (0)§ (0)# (0)‡ (0)‡‡
FXa (0)† (0)** (0)¶ 31 (0)§§
Chymotrypsin 41 110 (0) (0)‡ 254
Trypsin 4.3 (0)** (0)# 19 431
Elastase (0)† (0)§ (0)# (0)‡ -
*Test groups (X) are given in Figure 2. †Screened at 6 mM; ‡13 mM;
§16 mM; #19 mM; ¶60 mM; **90 mM; ††140 mM; ‡‡1 mM; §§70 mM.
Figure 2
Test groups (X) capable of interacting within the guanidino-binding site
(S1 site) of thrombin, when attached to a D-Phe–Pro scaffold. 
production of large combinatorial libraries is itself a time
consuming process. Consequently, ‘test scaffolds’ are fre-
quently used for initial evaluation of functional groups.
These scaffolds allow the rapid development of structure-
activity-relationships, even though they are ultimately
unsuitable for use as drugs. 
Table 1 outlines the results of an experiment using a 
combinatorial library D-Phe–Pro–(X), based on a D-Phe–
Pro-test scaffold. The poor bioavailability of thrombin
inhibitors that incorporate a guanidinium group may be
related to this group’s very basic pKa. Consequently, the
objective of the experiment was to discover groups (X)
that are capable of interacting with the guanidino-binding
site (S1 site) of thrombin and which would also provide
selectivity for thrombin over other serine proteases with
basic S1 specificity (e.g. plasmin). In this experiment, X
groups were chosen using a defined computational filter
applied to a database of commercially available amines
(X groups are given in Fig. 2). The computational filter
was designed to identify groups that provided a combina-
tion of geometrical, space-filling, and hydrogen-bonding
properties which, on the basis of the  thrombin structure,
could function as guanidine analogs. It is most notable
that several of the groups identified, although less potent
inhibitors than those containing the guanidinium group,
are considerably less basic, so they might be expected to
have better bioavailability. Figure 3 shows the superposi-
tion of several of these structures determined crystallo-
graphically, which generally agree with the expectations of
the computational-selection process [16].
Development of a scaffold that can generate nonpeptidic,
drug-like compounds is aided by the structural examina-
tion of as large a set of chemically different inhibitors as is
readily accessible. In the case of thrombin inhibitors, the
list of compounds is extensive and structural data are 
now available for many of them [10,17–23]. Figure 4 illus-
trates some representative structural classes of thrombin
inhibitors, while Figure 5 shows a superposition of their
three dimensional structures determined crystallographi-
cally. All of the inhibitors share a basic functional group
that binds in the enzyme S1 subsite, and a hydrophobic
moiety that binds in the ‘aryl subsite’, which has been pre-
viously identified in a number of thrombin inhibitor
studies [10,17–23]. In the current context, the key obser-
vation is that the connecting residues play the structural
role of scaffolds which differ in the manner in which they
project substituents into the aryl and S1 subsites. This
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Figure 3
Superposition of crystal structures of thrombin complexes with
D-Phe–Pro–X thrombin combinatorial library members based on
D-Phe–Pro-test scaffold, on the accessible surface of thrombin.
Chemical structures of X groups are given in Figure 2. (Compounds
are coded by color: 1, magenta; 2, yellow; 3, red; 4, blue; and 5,
orange). (RB and JS, unpublished observations.)
Figure 4
Chemical structures of representative scaffolds for protease-inhibitor
design [10,16]. 
information is key for two reasons: firstly, it facilitates the
design of new scaffolds with more desirable properties 
as drugs; and secondly, it shows how substituents that
have been identified from combinatorial synthesis on a
given scaffold can be recombined with other scaffolds to
produce improved compounds (Fig. 6).
Virtual libraries
Well developed combinatorial library strategies that are
able to explore detailed structure–activity relationships
generally require multistep synthetic protocols. These pro-
tocols have typically been carried out by modifying scaf-
folds that are reversibly linked to a solid-phase support,
such that reactions are driven to completion and isola-
tion of synthetic intermediates is facilitated. Scaffolds are
designed to be elaborated at two or more substitution sites
by reaction with custom or commercially available reagents.
Development of the structure–activity relationship gener-
ally requires the high-fidelity synthesis of individual com-
pounds. Although targeted-combinatorial schemes readily
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Figure 5
Superposition of representative scaffolds for protease-inhibitor design. Chemical structures are given in Figure 4. (a) Stereo superposition of 3705
(cyan), 3716 (magenta) and 3960 (orange). (b) Superposition of the same three structures on the accessible surface of thrombin.
Figure 6
Schematic of the interaction between
structure-based drug design and
combinatorial chemistry for drug discovery. 
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produce libraries of drug-like compounds with 106 or more
members, current automated equipment is practically
limited to the synthesis of 102–103 compounds for each
multistep synthesis cycle. This practical limitation on syn-
thetic throughput motivates the development of effective
computer-search strategies that can iteratively define and
refine the selection of sub-libraries that will best inves-
tigate the structure–property relationships for a given
library–target combination.
The most effective way to implement the search of large
combinatorial libraries is to precompute the structures and
properties of all synthetically accessible compounds within
the library and then to apply computational screens to this
‘virtual library’, in order to select subsets of compounds for
iterative rounds of synthesis and testing [7]. Structural fea-
tures of individual compounds can provide useful criteria
for ranking their predicted ability to bind the target recep-
tor and/or to discriminate against binding homologous pro-
teins. Although a great deal of effort has been expended in
developing accurate automated-docking algorithms [15],
these remain limited by difficulties in estimating the free
energy of ligand binding, as outlined in Figure 1. Instead,
approaches based on less precise and more rapidly com-
puted molecular properties seem effective in selecting
members of receptor-targeted libraries for investigation of
structure–activity correlations for a given receptor [24–26]. 
Selection of compounds for each round of synthesis can be
made on the basis of chemical diversity, similarity to pre-
viously discovered ligands (‘hits’), performance predicted
on the basis of structure–activity models, predicted ability
to fit the three-dimensional structure of the target, or 
the incorporation of substructures from known hits [7].
Recently, a computational method based on the use of 
a genetic algorithms was successfully used to predict
which compounds in a 160000-member combinatorial
library based on a single pot synthesis (Ugi reaction)
would inhibit thrombin [27]. In 20 cycles of 20 Ugi reac-
tions, the effective inhibitory concentration was decreased
from around 1mM to less than 1 mM. Genetic algorithms
have been used in a similar manner to identify optimal
stromelysin substrates from a hexapeptide library of 64
million members [28]. 
In addition to selecting molecules to explore specific fea-
tures suggested from a three-dimensional structural model,
computational filters can be designed to simultaneously
select molecules with properties that are thought to be
important in the ultimate development of a successful
drug (e.g. properties relating to bioavailability, toxicology,
etc.). Filters can be designed on the basis of computed
properties of the structures, such as computed water–
octanol partition coefficients (logP values), so that the dis-
tribution of logP values of the sub-library selected for syn-
thesis, corresponds to a range of known values for orally
acting drugs. In principle, any known property or struc-
ture–activity relationship can be introduced as a selection
criterion and can be used as part of a multi-parameter opti-
mization scheme for a given combinatorial sub-library. A
typical library-design optimization might identify a set of
1000 compounds from a virtual library containing 500000
compounds that fulfill the following parameters: meet geo-
metrical and functional criteria for fitting a target receptor;
meet structural criteria aimed at eliminating interactions
with homologous targets; maintain a desired range of logP
values; have less than four freely rotating bonds; and mini-
mize the cost of reagents. 
Structure-based recombination of optimized substituents
from independently developed drug-lead series or struc-
ture–activity correlations has proved a reliable means of
generating nanomolar potent inhibitors of thrombin that
show outstanding selectivity [10]. Combinatorial library
technology has the ability to collect this information much
more rapidly. By simultaneously tracking physical proper-
ties of library constituents, it should be possible to main-
tain a range of physical properties that are perceived to be
key in achieving high oral bioavailability [7,16], while opti-
mizing in vitro potency. These same recombination princi-
ples can be used to create large virtual libraries of protease
inhibitors, that can then be systematically investigated to
discover potent and specific inhibitors for a variety of pro-
teases of therapeutic interest. The ability to complement
the precision approach of structure-based design with the
sampling capability of combinatorial chemistry removes
many of the limitations of structure-based design and pro-
ductively focuses the combinatorial selection process. Key
to the evolving effectiveness of this integrated technology
is the continued development of mathematical approaches
that will optimally blend the structural requirements
defined by receptor-binding sites with other chemical and
physical properties that affect bioavailability and toxicity.
Indeed, the most interesting prospects for computer-
directed combinatorial chemistry lie in its ability to inves-
tigate multiple structure–activity models in parallel, thus
overcoming the one-at-a-time throughput limitations of
the conventional process of analog synthesis, testing and
redesign that characterize both structure-based design 
and conventional analog chemistry approaches to drug
discovery.
The integration of structure-based design and combinator-
ial chemistry can play a key role in the development of
new drugs whose molecular targets are being discovered as
a result of genome sequencing efforts. In many cases,
targets of potential therapeutic interest will be members of
larger protein classes, some of whose members have known
three-dimensional structures. The availability of structural
information will enable the development of targeted com-
binatorial libraries, based on pharmacophores that are
known to be active for the target class. These libraries can
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be searched using the same kinds of strategies as those
outlined here for thrombin, in order to produce new phar-
maceuticals with the specificity for a receptor or enzyme
sub-type that is required for a safe and efficacious drug. 
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